Related coverage linked through entity extraction aliases.
Feb 27, 2026
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Feb 20, 2026
Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.
Feb 13, 2026
A matched analysis of 923 men found salvage focal therapy and radical prostatectomy achieved comparable 10-year cancer-specific survival for prostate cancer recurring after radiotherapy, though surgery carried significantly higher complication rates.
